Physicians should use evidence-based guidelines as a starting point to make sound clinical treatment decisions for a patient's individual medical needs.
Douglas E. Paull, MD, MS and Paul N. Uhlig, MD, MPA
Risk managers can help patient-subjects and clinician-researchers make informed novel device implantation decisions in the absence of preclinical trial data.
AMA J Ethics. 2020;22(11):E911-918. doi:
10.1001/amajethics.2020.911.
The authors of a recent journal article believe that most doctors and clinical trial sponsors would not object to changes in regulations requiring doctors to disclose financial incentives to their patients.
The financial generosity of the pharmaceutical industry to provide funding for medical education tempts a compromise of professional standards and ethics.
In April 2002, many pharmaceutical companies adopted PhRMA code, an attempt to self-regulate the pharmaceutical industry's marketing to physicians and other health care professionals.
Adrienne W. Henize, JD and Andrew F. Beck, MD, MPH
Data on certain chronic conditions’ prevalence, incidence of potentially preventable morbidity, and health-harming legal factors influence approaches to care.
AMA J Ethics. 2024;26(8):E648-654. doi:
10.1001/amajethics.2024.648.
Professor Adrienne W. Henize joins Ethics Talk to discuss her article, coauthored with Dr Andrew F. Beck: “What Are Epidemiological Foundations for Integrating Legal Services Into Health Care Settings?”